Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163137 · ClinicalTrials.gov registry record · Phase 3
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
A Phase 3 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
NCT00163137 is a Phase 3 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 540 participants.
The verdict
NCT00163137, a Phase 3 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
Study Summary
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
Interventions
- DRUG Placebo
- DRUG raloxifene
- DRUG lasofoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00163137
The ClinicalTrials.gov registry entry for NCT00163137 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00163137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00163137 about?
NCT00163137 is a clinical study titled "Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss". To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
What is the current status of trial NCT00163137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2003-05. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00163137?
The interventions under investigation include: Placebo (DRUG), raloxifene (DRUG), lasofoxifene (DRUG).
Who is sponsoring clinical trial NCT00163137?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.